Jan 10
2026
Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
SAN DIEGO, Jan. 9, 2026 /PRNewswire/ -- Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy,...
Read More
Dec 10
2025
Phanes Therapeutics to present Phase 1/2 study results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic PDAC at ASCO GI 2026
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Sep 9
2025
Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy
SAN DIEGO, Sept. 8, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 27
2025
Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy
SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 5
2025
Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Feb 19
2025
Phanes Therapeutics announces first patient dosed in clinical study of peluntamig (PT217) in combination with chemotherapy
SAN DIEGO, Feb. 19, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Dec 4
2024
Phanes Therapeutics’ PT217 granted Fast Track designation by the FDA for NEPC
This is the second Fast Track Designation granted to PT217 by the agency SAN DIEGO, Dec. 4, 2024 /PRNewswire/ -- Phanes Therapeutics,...
Read More
Nov 6
2024
Phanes Therapeutics announces the appointment of gastrointestinal oncologist Prof. Zev Wainberg to its Clinical Advisory Board
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Oct 8
2024
Phanes Therapeutics announces first patient dosed in clinical study of PT886 in combination with KEYTRUDA® (pembrolizumab)
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Sep 9
2024
Phanes Therapeutics announces first patient dosed in clinical study of PT886 in combination with chemotherapy
SAN DIEGO, Sept. 9, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
